Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
REVIEWS CORTICAL INHIBITORY NEURONS AND SCHIZOPHRENIA David A. Lewis*‡, Takanori Hashimoto* and David W. Volk* Abstract | Impairments in certain cognitive functions, such as working memory, are core features of schizophrenia. Convergent findings indicate that a deficiency in signalling through the TrkB neurotrophin receptor leads to reduced GABA (γ-aminobutyric acid) synthesis in the parvalbumin-containing subpopulation of inhibitory GABA neurons in the dorsolateral prefrontal cortex of individuals with schizophrenia. Despite both pre- and postsynaptic compensatory responses, the resulting alteration in perisomatic inhibition of pyramidal neurons contributes to a diminished capacity for the gamma-frequency synchronized neuronal activity that is required for working memory function. These findings reveal specific targets for therapeutic interventions to improve cognitive function in individuals with schizophrenia. PSYCHOSIS This refers to distortions in inferential thinking, such as delusions (fixed, false beliefs that are firmly held in the face of contradictory evidence), and perceptual disturbances, such as hallucinations. Auditory hallucinations, usually experienced as voices distinct from one’s own thoughts, are most common in schizophrenia. Departments of *Psychiatry and ‡Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. Correspondence to D.A.L. e-mail: [email protected] doi:10.1038/nrn1648 312 | APRIL 2005 | VOLUME 6 Schizophrenia is a devastating illness that affects approximately 1% of the world’s population1. Affected individuals frequently come to clinical attention during late adolescence or early adulthood, about 10% will eventually commit suicide and most experience a lifetime of disability. As a result, schizophrenia is associated with a substantial emotional burden for the families of those affected and it incurs tremendous economic costs for society in terms of medical expenditure and lost productivity. The risk of developing schizophrenia is directly proportional to the degree of genetic relatedness to an affected individual2, and several putative susceptibility genes for schizophrenia have been identified3. However, the degree of risk conferred by each gene seems to be small, and, for most genes, the biological basis of the increased risk for illness remains unclear. Furthermore, the degree of concordance for schizophrenia among individuals with the same genetic make-up is only about 50% (REF. 2), which indicates that genetic liability alone might not be sufficient to cause the clinical features of the illness. Consistent with this interpretation, various environmental events across development, from advanced paternal age at the time of conception to frequent cannabis use during adolescence, seem to increase the likelihood of developing schizophrenia later in life4. Therefore, the etiology of schizophrenia is thought to require an interaction between genetic susceptibility and environmental risk factors, which alters neurodevelopmental processes that occur before the onset of the diagnostic features of the illness. Although PSYCHOSIS is usually the presenting and most striking clinical aspect of schizophrenia, it is not diagnostic of the disorder. Schizophrenia is recognized by the presence of impairments in social and occupational functioning (BOX 1) that result from the confluence of a range of disturbances in brain function, including abnormalities in perception, inferential thinking, fluency and production of language, expression of emotion, capacity for pleasure, volition and attention5. Of the many clinical features of schizophrenia, disturbances in certain cognitive processes, such as impairments in attention, memory and executive functions (that is, the ability to plan, initiate and regulate goaldirected behaviour), might represent the core features of the illness6. Cognitive abnormalities have been found throughout the life span of individuals with schizophrenia, including during childhood and adolescence7, and at the initial onset of psychosis8. The unaffected relatives of individuals with schizophrenia also show similar, although milder, cognitive deficits9, which indicates that the cognitive deficits are not caused by treatment with antipsychotic medications or the chronic nature of the illness. The cognitive disturbances of schizophrenia have www.nature.com/reviews/neuro REVIEWS Box 1 | Diagnostic criteria for schizophrenia At present, no findings from laboratory procedures, neuroimaging methods or psychological tests are diagnostic of schizophrenia. Schizophrenia is diagnosed on the basis of the clinical syndrome, that is, the clustered appearance of a characteristic set of signs and symptoms. For the purpose of diagnostic reliability, these features have been formulated into specific criteria5. The first diagnostic criterion requires the presence of two or more of the following clinical features: delusions, hallucinations, disorganized thinking (as reflected by tangential or incoherent speech), grossly disorganized or catatonic behaviour, and negative symptoms. The latter include altered emotional expression (for example, flat affect), poverty of speech (for example, alogia) and avolition (for example, the inability to initiate and persist in goal-directed activities). The second diagnostic criterion requires evidence of social or occupational dysfunction, such as deterioration in interpersonal relationships, work habits or personal hygiene, from the level achieved prior to the appearance of the clinical features. Third, the signs of the disturbance must be continuously present for at least six months. Fourth, it must be clear that the clinical features are not attributable to another disorder, including substance abuse.Although establishing the validity of these criteria remains an ongoing area of investigation, the application of these criteria is very reliable, which results in a high degree of concordance across research clinicians in the diagnosis of schizophrenia.At present, available treatments for schizophrenia are primarily effective in suppressing the psychotic features of the illness; they have limited impact on negative symptoms, and do not appreciably improve the social or occupational outcome for most individuals. WORKING MEMORY The active maintenance of limited amounts of information for a short period of time to guide thought processes or sequences of behaviour. Working memory is typically assessed through delayed response tasks in which a stimulus cue is briefly presented and removed, a delay period ensues, and then a response is required based on information contained in the stimulus cue. a greater negative impact on daily activities than do the psychotic symptoms, and the degree of cognitive dysfunction might be the best predictor of long-term functional outcome for individuals with schizophrenia10. Despite the clinical importance of these cognitive abnormalities, there are no approved pharmacological treatments for these deficits. Furthermore, all medical treatments currently used for schizophrenia, which primarily suppress the psychotic features, were discovered by chance. The development of more effective treatments, and possibly of secondary prevention measures, requires greater knowledge of the underlying disease process (FIG. 1). Specifically, how do complex and variable combinations of genetic liabilities, environmental risk factors and developmental processes alter the structure and function of the brain and produce the characteristic clinical symptoms of schizophrenia? Typically, the starting point Pathogenesis (reduced signalling through TrkB) Etiology Pathophysiology (reduced gamma band power) Pathological entity (deficit in chandelier cell-mediated inhibition) Prevention Clinical syndrome (impaired working memory) Treatment (GABAA α2 agonist) Figure 1 | Components of the disease process of schizophrenia. The cluster of clinical signs and symptoms (clinical syndrome) characteristic of a brain disorder, such as schizophrenia, is the result of some cause or set of causes (etiology). The cause or causes induce the disease mechanisms (pathogenesis), which produce abnormalities in the brain (pathological entity) that alter its function (pathophysiology). The development of effective treatments or preventative measures requires the ability to interrupt or reverse the pathophysiological processes and pathogenetic mechanisms, respectively. For each component of the disease process of schizophrenia, the data reviewed in this article provide convergent evidence for the indicated abnormalities. TrkB, tyrosine kinase Trk (tropomyosin-related kinase) receptor B. NATURE REVIEWS | NEUROSCIENCE for addressing this question is the clinico-pathological correlation — the identification of a pathological entity that is associated with the clinical syndrome. An important challenge in schizophrenia research has been to identify a pathological entity that is associated with the core cognitive deficits of the illness. In this review, we illustrate one strategy for characterizing the components of the disease process of schizophrenia, beginning with the cognitive features of the clinical syndrome. Specifically, we review evidence that certain cognitive abnormalities in schizophrenia reflect pathology in specific cortical inhibitory circuits; that these pathological alterations might arise from specific pathogenetic mechanisms; and that these pathological alterations result in pathophysiological processes that have implications for new therapeutic interventions. As such, this article is not intended to provide a comprehensive review of the abnormalities found in inhibitory neurons in individuals with schizophrenia, which have been reviewed elsewhere11,12. Working memory deficits in schizophrenia Certain crucial cognitive deficits in schizophrenia seem to reflect alterations in executive control, which includes context representation and maintenance functions, such as WORKING MEMORY, that depend on the DORSOLATERAL 13 PREFRONTAL CORTEX (DLPFC) . Individuals with schizophrenia tend to perform poorly on working memory tasks and to show reduced DLPFC activation when attempting to carry out such tasks14,15. In addition, under conditions in which individuals with schizophrenia perform normally on working memory tasks, activity in the DLPFC can be increased, which indicates that the DLPFC operates less efficiently16. Several findings support the relevance of these alterations in DLPFC function to the disease process of schizophrenia. First, individuals with other psychotic disorders17 or major depression18 show normal activation of the DLPFC when carrying out working memory tasks, which indicates that the abnormalities observed in schizophrenia are, at least in part, specific to the clinical syndrome of schizophrenia. Second, the severity of deficits in activation of the DLPFC, but not of other cortical regions, during working memory tasks predict the severity of cognitive disorganization symptoms in individuals with schizophrenia15. Third, it has been suggested that reduced working memory capacity might be rate limiting in the performance of other cognitive tasks in schizophrenia19. Therefore, working memory deficits seem to be a central feature of schizophrenia, and identifying the pathological entity (or entities) in the DLPFC that produces these functional alterations is essential for understanding the underlying disease process. A pathological entity in schizophrenia Working memory and inhibition in the DLPFC. Although working memory is an emergent property of a neuronal network that is distributed across a number of brain regions20, it depends on the coordinated and sustained firing of subsets of DLPFC PYRAMIDAL NEURONS between the temporary presentation of a stimulus cue VOLUME 6 | APRIL 2005 | 3 1 3 REVIEWS mechanism for the disturbances in working memory in individuals with schizophrenia. Consistent with this view, tissue concentrations of the mRNA that encodes the 67 kiloDalton isoform of glutamic acid decarboxylase (GAD67), an enzyme that synthesizes GABA, are reduced in the DLPFC of individuals with schizophrenia26–31. Indeed, reduced GAD67 mRNA expression in the DLPFC is one of the most consistent findings in postmortem studies of individuals with schizophrenia32. The deficit in GAD67 mRNA seems to be accompanied by a corresponding decrease in the cognate protein, although this has been less extensively studied28. By contrast, mRNA and protein levels of GAD65, another enzyme that synthesizes GABA, are not altered in the DLPFC of people with schizophrenia28, and the density of GAD65-immunoreactive axon terminals also remains unchanged33. Interestingly, elimination of the Gad65 gene in mice does not alter cortical levels of GABA34, whereas reductions in GAD67 mRNA are associated with marked decreases in cortical GAD activity and GABA content35. CRC 1 DB 2 DB G 3 WA ais Ch Ng 4 5 M 6 Grey matter White matter Figure 2 | Morphological and biochemical features of subpopulations of cortical GABA neurons in the dorsolateral prefrontal cortex. The diagram illustrates the calcium-binding proteins — parvalbumin (blue), calbindin (red) and calretinin (yellow) — and the locations of inhibitory synaptic inputs to a pyramidal neuron (green) by different morphological classes of cortical GABA (γ-aminobutyric acid) neurons. The chandelier (Ch) and wide arbor (WA) or basket neurons provide inhibitory input to the axon initial segment (ais) and the cell body proximal dendrites, respectively, of pyramidal neurons. By contrast, the calbindin-expressing double bouquet (red DB), neurogliaform (Ng) and Martinotti (M) neurons tend to provide inhibitory inputs to the distal dendrites of pyramidal neurons. Finally, calretinin-expressing (yellow) DB and Cajal–Retzius cell (CRC) appear to target both pyramidal cell distal dendrites and other GABA (G) neurons. 1–6, layers of dorsolateral prefrontal cortex. Modified, with permission, from REF. 41 (1994) John Wiley & Sons, Inc. DORSOLATERAL PREFRONTAL CORTEX (DLPFC). Those regions on the dorsal surface of the primate frontal lobe that are located rostral to the motor and premotor regions, and which include Brodmann’s areas 9 and 46. PYRAMIDAL NEURONS These constitute ~75% of cortical neurons, and are recognized by their triangular cell bodies, a single apical dendrite directed toward the cortical surface and an array of basilar dendrites. The dendrites of these neurons are studded with many spines, and their axons project into the white matter and provide excitatory projections to other cortical regions or subcortical structures. 314 | APRIL 2005 | VOLUME 6 and the later initiation of a behavioural response21. Although other neurotransmitter systems are also involved, DLPFC neurons that use the inhibitory neurotransmitter GABA (γ-aminobutyric acid) seem to be crucial for such synchronization of pyramidal neuron activity during working memory processes. For example, fast-spiking GABA NEURONS in the monkey DLPFC are active during the delay period of working memory tasks22, and are necessary for task-related neuronal firing and the spatial tuning of neuronal responses during working memory 23. In addition, the injection of GABA antagonists into the DLPFC disrupts working memory24. Constantinidis and colleagues25 suggested that during working memory tasks inhibition might serve both a spatial role (controlling which DLPFC pyramidal neurons are activated during working memory) and a temporal role (controlling when they are active during the different phases of working memory). These findings indicate that impairments in GABAmediated inhibition in the DLPFC could provide a Gene expression deficits in a subset of GABA neurons. Cortical GABA neurons are heterogeneous, with various subpopulations that can be distinguished by a combination of morphological, physiological and molecular attributes (FIG. 2). Distinct subpopulations of GABA neurons seem to have specialized functions in regulating pyramidal neuron activity36,37. For example, the chandelier (or axo–axonic) subpopulation of GABA neurons express the calcium-binding protein parvalbumin38, have a fast-spiking, non-adapting firing pattern39 and project a linear array of axon terminals (termed cartridges) that synapse exclusively on the axon initial segments of pyramidal neurons40 (FIG. 3a,b). Wide arbor (basket) cells in the monkey DLPFC also express parvalbumin41 and have fast-spiking electrophysiological features that are indistinguishable from those of chandelier neurons42. However, the axons of wide arbor neurons have a much larger spread than those of chandelier cells, and their axon terminals mainly target the cell bodies and proximal dendrites of pyramidal neurons38. The proximity of the perisomatic inhibitory synapses — formed by parvalbumin-expressing chandelier and wide arbor neurons — to the site of action potential generation in pyramidal neurons indicates that these GABA neurons might be specialized to regulate the output of pyramidal neurons. The calcium-binding protein calbindin is expressed in double bouquet, neurogliaform and Martinotti cells, which are not fast-spiking and provide axon terminals that synapse on the distal dendrites of pyramidal cells43,44. Finally, ~50% of GABA neurons in the monkey DLPFC, many of which are double bouquet cells, express the calcium-binding protein calretinin41, have a regularspiking, adaptive firing pattern39,44 and produce axon terminals that target distal dendritic spines or shafts on pyramidal cells or other GABA neurons45. So, the functional consequences of a deficit in GAD67 in schizophrenia depend on whether all or a specific subpopulation (or subpopulations) of GABA neurons are affected. www.nature.com/reviews/neuro REVIEWS a b neuron correlated strongly with the change in density of GAD67 mRNA-positive neurons. These findings indicate that GAD67 mRNA expression was markedly reduced in parvalbumin-expressing neurons that also had reduced, but still detectable, levels of parvalbumin mRNA. This was confirmed by dual label in situ hybridization studies, which revealed that ~50% of parvalbumin mRNApositive neurons lacked detectable levels of GAD67 mRNA in individuals with schizophrenia47. These findings are consistent with immunocytochemical studies that failed to find a reduction in the densities of parvalbumin-positive neurons in the DLPFC of individuals with schizophrenia48,49. So, it seems that the number of parvalbumin-expressing GABA neurons are not reduced in the DLPFC of individuals with schizophrenia, but that they have decreased expression of several important genes and might, therefore, be functionally impaired. c 10 µm Figure 3 | Pre- and postsynaptic markers of chandelier neuron inputs to the axon initial segment of pyramidal neurons. a,b | Immunoreactivity for GABA (γ-aminobutyric acid) transporter 1 (GAT1; a) and parvalbumin (b) clearly identifies vertical arrays of chandelier neuron axon terminals (cartridges) that are located below the cell bodies of unlabelled pyramidal neurons. c | Immunoreactivity for the α2 subunit of the GABAA (GABA type A) receptor is localized postsynaptically, in the axon initial segment of pyramidal neurons. Modified, with permission, from REF. 116 © (2003) John Wiley & Sons, Inc. GABA NEURONS These comprise ~25% of cortical neurons, have smooth or sparsely spiny dendrites and provide axons that project locally within the cortical grey matter. Studies of GAD67 mRNA expression at the cellular level showed that, in individuals with schizophrenia, the density of neurons with detectable levels of GAD67 mRNA was significantly decreased in DLPFC layers 3–5, but not in layer 6 (REFS 26,27). Furthermore, in neurons with detectable levels of GAD67 mRNA, the expression level per neuron did not differ from control values27. These observations indicate that in individuals with schizophrenia, most DLPFC GABA neurons express normal levels of GAD67mRNA. However, ~25–30% of GABA neurons do not express this transcript at a detectable level. In the same cohort of individuals, expression of the GABA membrane transporter 1 (GAT1) — a protein responsible for reuptake of released GABA into nerve terminals — was also decreased, with almost identical cellular patterns46. Therefore, in schizophrenia, both the synthesis and reuptake of GABA seem to be greatly reduced in a subset of DLPFC inhibitory neurons. Recent evidence indicates that the affected GABA neurons include those that contain the calcium-binding protein parvalbumin, which is present in ~25% of GABA neurons in the primate DLPFC41. In individuals with schizophrenia, the expression of parvalbumin mRNA was shown to be significantly decreased in layers 3 and 4, but not in layers 2, 5 or 6, of the DLPFC47 (FIG. 4). However, in contrast to the findings for GAD67 and GAT1 mRNAs, the density of neurons with detectable levels of parvalbumin mRNA was unchanged in individuals with schizophrenia, although the expression level per neuron was significantly decreased. In the same individuals, the parvalbumin mRNA expression level per NATURE REVIEWS | NEUROSCIENCE Alterations in chandelier neurons. In addition to the unique role of parvalbumin-expressing GABA neurons in regulating pyramidal cell activity, their distinctive developmental trajectories in the monkey DLFPC, especially during adolescence (BOX 2), indicate that alterations in these neurons might contribute to working memory dysfunction in schizophrenia. Consistent with this hypothesis, the density of chandelier neuron axon cartridges that were immunoreactive for GAT1 was significantly reduced in the DLPFC of individuals with schizophrenia50 (FIG. 5), with the most extensive reduction seen in the middle cortical layers51. By contrast, immunoreactivity of GAT1 in other axon terminal populations was unchanged50. Together with the gene expression studies reviewed above, these findings indicate that chandelier neurons in the DLPFC of individuals with schizophrenia express decreased levels of parvalbumin mRNA and undetectable levels of GAD67 and GAT1 mRNAs, the latter of which results in reduced GAT1 protein in their axon cartridges. Despite the convergence of these findings for a common GABA-containing cell type, it is unclear how GABA neurotransmission at the synapse between the chandelier neuron and the pyramidal cell axon initial segment is altered in schizophrenia. These findings could reflect deficient inhibition, resulting from a primary reduction in GABA synthesis, or excessive inhibition, secondary to a reduction in GABA reuptake. To distinguish between these alternatives, it might be useful to analyse GABAA (GABA type A) receptors on the postsynaptic targets of chandelier neuron axons. GABAA receptors are pentameric hetero-oligomers that are composed of subunits from seven different classes, several of which have more than one member. For example, most GABAA receptors in the cortex contain one of six α subunits that have different subcellular distributions and physiological properties52. Although present in only ~15% of cortical GABAA receptors53, the α2 subunit is found at >95% of inhibitory synapses onto pyramidal neuron axon initial segments54 (FIG. 3c), especially in the superficial layers of the human cerebral cortex55. In addition, GABAA receptors that have the α2 VOLUME 6 | APRIL 2005 | 3 1 5 REVIEWS a b 120 PV mRNA 100 80 3 60 nCi/g 1 2 4 Control Schizophrenia ‡ * 40 5/6 20 White matter 0 1 2 3 4 5/6 4 5/6 Cortical Layer Low density High density 120 CR mRNA 100 80 3 60 4 nCi/g 1 2 Control Schizophrenia 40 5/6 20 White matter 1 mm 0 1 2 3 Cortical Layer Figure 4 | Expression of parvalbumin and calretinin mRNAs in the dorsolateral prefrontal cortex. a | Pseudocoloured autoradiograms showing the different laminar distribution patterns of the GABA (γ-aminobutyric acid) neurons that express parvalbumin (PV) or calretinin (CR) mRNAs in the dorsolateral prefrontal cortex of human control subjects. b | The bar graphs show the mean (SD) expression level of each transcript, by cortical layer, in individuals with schizophrenia and matched control subjects. The expression of parvalbumin mRNA is significantly decreased in layers 3–4 of individuals with schizophrenia, whereas the expression of calretinin mRNA is unchanged across all layers. nCi/g, nanoCuries/gram; 1–6, layers of dorsolateral prefrontal cortex. *P = 0.012, ‡P = 0.005. Modified, with permission, from REF. 47 © (2003) Society for Neuroscience. subunit seem to have a higher affinity for GABA, which results in faster activation and slower deactivation times than GABAA receptors that have the more common α1 subunit56,57. So, GABAA receptors that have the α2 subunit seem to be anatomically located and functionally specialized to mediate a potent inhibitory influence on the output of pyramidal neurons. In the DLPFC of individuals with schizophrenia, the density of pyramidal neuron axon initial segments that are immunoreactive for the GABAA α2 subunit is increased by >100% compared with control subjects58 (FIG. 5). This seems to reflect higher levels of α2 subunits at the axon initial segment rather than an increase in the density of pyramidal neurons59 or of their axon initial segments60. Furthermore, the density of α2-immunoreactive axon initial segments was inversely correlated with the density of GAT1-immunoreactive cartridges in the same individuals with schizophrenia (FIG. 5). So, in the DLPFC of individuals with schizophrenia, GABAA receptors seem to be upregulated at pyramidal neuron axon initial segments in response to deficient GABA release from chandelier axon terminals. Furthermore, as changes in GAD are not seen in mice that lack GAT1 (REF 61), both the increase in postsynaptic GABAA receptors and the decrease in presynaptic GAT1 are likely to be compensatory responses to a more primary deficit in GAD67 mRNA expression. 316 | APRIL 2005 | VOLUME 6 Although they are more difficult to assess, similar preand postsynaptic changes might also occur in the inputs of parvalbumin-expressing wide arbor neurons to the perisomatic region of pyramidal neurons. For example, the density of parvalbumin-immunoreactive puncta — possibly the axon terminals of wide arbor neurons62 — is reduced in the middle but not the superficial layers of the DLPFC in individuals with schizophrenia63, which parallels the laminar pattern of decreased expression of parvalbumin mRNA in schizophrenia (FIG. 4). Furthermore, the increased density of GABAA receptors in the DLPFC of individuals with schizophrenia in ligand binding studies64,65 was most prominent at pyramidal neuron cell bodies65. These data indicate that, in schizophrenia, GABAA receptors at the soma and axon initial segments of pyramidal neurons might be locally upregulated in response to a reduction in perisomatic inhibitory input from chandelier and wide arbor neurons (FIG. 6). Given the restricted locations of these synaptic alterations, and the fact that inhibitory inputs to the cell bodies and axon initial segments of pyramidal neurons represent <10% of the total complement of inhibitory synapses on the cell, it is not surprising that changes in the mRNA levels of the main postsynaptic GABAA receptor subunits have not been detected in the DLPFC of individuals with schizophrenia66. However, some studies have reported increases in the mRNA for the α1 subunit67,68. www.nature.com/reviews/neuro REVIEWS Box 2 | Postnatal development of chandelier neuron inputs Specificity to the disease process of schizophrenia. Whether these findings represent a clinically relevant pathological entity in schizophrenia depends, in part, on the extent to which they are specific to the disease process of schizophrenia. In this regard, neither parallel studies in individuals with other psychiatric disorders (FIG. 5), nor studies in monkeys that were chronically exposed to antipsychotic medications in a fashion that mimics the clinical treatment of schizophrenia, replicated the alterations in markers of GABA neurotransmission that are described above27,46,47,51,58. Furthermore, these deficits seem to be relatively specific to parvalbumin neurons and are not found in many other GABA neurons in the DLPFC in individuals with schizophrenia. For example, most GABA neurons in the DLPFC express normal levels of GAD67 and GAT1 mRNAs27,46. Moreover, the expression of calretinin mRNA, which is found in about half of the GABA neurons in the primate DLPFC41, is also unchanged in individuals with schizophrenia47 (FIG. 4), as is the density of calretinin-immunoreactive puncta, which presumably NATURE REVIEWS | NEUROSCIENCE PV varicosity number per 400 µm2 Cartridge and ais number per mm2 The axon terminals of chandelier Birth 3m 15 m 42 m Adult 20 350 neurons are vertical arrays of boutons (cartridges) that are immunoreactive for parvalbumin (PV) or GABA 300 membrane transporter 1 (GAT1), and outline the axon initial segment of 15 pyramidal neurons (FIG. 3a,b). PV 250 varicosities Although the developmental time course differs somewhat for these two P markers, as illustrated in the diagram, 200 the density of labelled cartridges is low GABAA 10 PV α2 ais in the DLPFC of newborn monkeys, cartridges 150 increases to reach a peak before the GAT1 cartridges onset of puberty, and then declines markedly during adolescence (shaded 100 area between 15 and 42 months of age) 5 to adult levels116. These density changes in parvalbumin- and GAT50 immunoreactive cartridges seem to reflect developmental shifts in the concentration of these proteins (and 0 0 so in the detectability of cartridges) as 0.01 0.1 1 10 100 1,000 Log age (months) cartridges are readily visualized with the Golgi technique over this same time period117. Interestingly, the peak and subsequent decline in the density of labelled cartridges occurs prior to the age at which the peak density of parvalbumin-immunoreactive varicosities — putative axon terminals from the wide arbor class of parvalbumin-expressing GABA (γ-aminobutyric acid) neurons (FIG. 2) — is achieved62. Postsynaptically, the detectability of the α2 subunit of the GABAA (GABA type A) receptor in pyramidal neuron axon initial segment is high at birth, and then markedly declines during adolescence before stable adult levels are achieved. The marked developmental changes in these pre- and postsynaptic markers of inhibition at the inputs from chandelier and wide arbor cells to the perisomatic region of pyramidal neurons indicate that the capacity to synchronize pyramidal neuron output in the DLPFC might be in substantial flux until adulthood. Consequently, the protracted developmental time course of improvements in performance on working memory tasks118 might depend on both refinements in the number of excitatory connections among pyramidal neurons and changes in their proximal inhibitory inputs (for a review, see REF. 119). These developmental changes during adolescence might contribute to unmasking the consequences of inherited abnormalities in the regulation of GABA mediated neurotransmission and might help to explain why certain life experiences during adolescence (for example, stress or cannabis exposure) seem to increase the risk for schizophrenia4. Panel adapted, with permission, from REF. 116 (2003) John Wiley & Sons, Inc. represent a substantial proportion of GABA axon terminals48. However, abnormalities in parvalbumin neurons alone might not completely account for the deficits in expression of GAD67 and GAT1 mRNAs, as such changes were also observed in cortical layers 1 and 2, where relatively few parvalbumin-expressing GABA neurons are located41, and where no changes in the expression of parvalbumin mRNA were found47 (FIG. 4). Regional specificity. Are these abnormalities in GABA neurotransmission restricted to the DLPFC, or do they represent a disturbance that is distributed across other cortical regions that might contribute to other aspects of the clinical syndrome of schizophrenia? Initial studies of the hippocampus reported a decrease in the density of non-pyramidal, putative GABA neurons69 and an increase in GABAA receptor binding 69 in schizophrenia. However, a recent study from the same research group did not detect a difference in the expression of either GAD67 or GAD65 mRNAs in the hippocampus of individuals with schizophrenia, although both VOLUME 6 | APRIL 2005 | 3 1 7 REVIEWS 150 Schizophrenia Major depression Change from matched control group (%) 100 50 0 –50 GAT1 cartridge α2-ais –100 Figure 5 | Changes in pre- and postsynaptic markers of GABA input to the axon initial segment of pyramidal neurons in the dorsolateral prefrontal cortex of individuals with schizophrenia. The bar graph shows the mean percentage change in the densities of GABA (γ-aminobutyric acid) transporter 1 (GAT1)-immunoreactive cartridges and GABAA (GABA type A) receptor α2 subunit immunoreactive axon initial segments (ais) in the dorsolateral prefrontal cortex of individuals with schizophrenia or major depressive disorder compared with matched control subjects. Note that the changes of these markers in schizophrenia are reciprocal and seem to be disease-specific. Modified, with permission, from REF. 58 (2002) Oxford University Press. transcripts were decreased in individuals with bipolar disorder70. In the anterior cingulate cortex of individuals with schizophrenia, the densities of non-pyramidal neurons69 and of neurons that were immunoreactive for the calcium-binding protein calbindin71 were reported to be reduced in layer 2, as was the density of GAD67 mRNA-positive neurons72. In the superior temporal gyrus, the level of GAD67 mRNA was reduced67, as was the density of GAT1-immunoreactive axon cartridges, although to a lesser extent than in the DLPFC of the same individuals with schizophrenia73. So, although the current knowledge base is not sufficient to provide a definitive answer, the available data indicate that changes in GABA neurotransmission in schizophrenia might be a common feature of neocortical regions, but not of the hippocampus70, and that the magnitude of these changes might be larger in the DLPFC than in other neocortical regions. Uncovering a pathogenetic mechanism REELIN Reelin is a large protein that is secreted into the extracellular matrix by Cajal–Retzius cells. It regulates the migration of cortical neurons during development. The absence of reelin in the reeler mouse results in a distinctive alteration of the normal cellular architecture of the cortex. 318 | APRIL 2005 | VOLUME 6 The importance of the changes in parvalbumin-expressing GABA neurons as a pathological entity in schizophrenia would be strengthened by showing that they co-occur in the illness with abnormalities that represent potential pathogenetic mechanisms, and by confirming in animal models that these correlations represent cause and effect. In this section, we review the evidence for several pathogenetic mechanisms that could produce such changes in GABA neurons in the DLPFC. Reduced levels of reelin. Reductions in mRNA and protein levels for REELIN, in association with deficits in the expression of GAD67 mRNA, have been reported in the DLPFC and several other brain regions in individuals with schizophrenia67. However, in contrast to control subjects, the levels of reelin and GAD67 mRNAs were not correlated in individuals with schizophrenia28. Reelin is expressed in ~50% of GABA neurons in the adult rodent cortex74, and heterozygote reeler mice (expressing 50% of the normal levels of reelin) show decreased GAD67 mRNA expression75. However, reelin is apparently not expressed in parvalbumin-expressing cortical GABA neurons76; therefore, the relationship between decreased reelin expression and the preferential reduction of GAD67 mRNA expression in parvalbumin-positive neurons in individuals with schizophrenia requires further study. Reduced excitatory drive. It has been suggested that the deficit in GAD67 mRNA expression represents an activity-dependent change in response to reduced activity of excitatory circuits in the DLPFC26. One source of such excitatory inputs is the mediodorsal nucleus of the thalamus, which is the principal source of thalamic projections to the DLPFC. Interestingly, initial studies reported that the number of neurons in this nucleus was reduced in individuals with schizophrenia; however, recent studies have not confirmed these observations (for a review, see REF. 77). Furthermore, experimental reductions in neuron number in the mediodorsal thalamus of rodents did not change the expression of GAD67 mRNA in the prefrontal cortex78. However, other changes, such as a decreased density of dendritic spines (a marker of excitatory synaptic inputs to pyramidal neurons) in the DLPFC of individuals with schizophrenia79,80, are consistent with reduced excitatory drive in DLPFC circuits, although the source of these altered inputs has yet to be determined. In addition, convergent lines of evidence indicate that schizophrenia might be associated with reduced neurotransmission through NMDA (N-methyl-D-aspartate) glutamate receptors81 and, interestingly, the administration of NMDA receptor antagonists to rodents reduces parvalbumin levels in cortical GABA neurons82. One potential source of such altered excitatory inputs is the hippocampus. Various structural and functional abnormalities have been observed in the hippocampi of individuals with schizophrenia, and some of these seem to be correlated with alterations in the DLPFC. For example, Weinberger and colleagues observed that tissue levels of N-acetyl-aspartate, a putative marker of neuronal integrity, were decreased in the hippocampus and DLPFC, but not in other brain regions, of individuals with schizophrenia83. To explore this association, they used a rodent model in which lesions of the ventral hippocampus are created neonatally 84. In adulthood, these animals, in addition to mimicking a number of other phenotypic features of schizophrenia, show deficits in GAD67 expression in the prefrontal cortex85. However, whether the deficits in GAD67 mRNA expression show the cell type specificity, and are accompanied by the other changes in GABA markers that are present in schizophrenia, has not yet been investigated. www.nature.com/reviews/neuro REVIEWS 1 2 GAD67 GAT1 CR mRNAs 3 GAT1 IR 4 GABAA α2 IR 5 6 GAD67 GAT1 PV mRNAs Grey matter White matter Figure 6 | Schematic summary of alterations in GABA circuitry in the dorsolateral prefrontal cortex of individuals with schizophrenia. Reduced levels of gene expression in chandelier neurons (blue) are associated with a decrease in immunoreactivity (IR) for GABA (γ-aminobutyric acid) transporter 1 (GAT1) in the axon cartridges of these neurons and an upregulation of GABAA (GABA type A) receptor α2 subunit immunoreactivity in the postsynaptic axon initial segment of pyramidal neurons (green). Gene expression in calretinin (CR)-expressing subpopulations of GABA neurons does not seem to be altered (yellow). GAD67, 67 kD isoform of glutamic acid decarboxylase; PV, parvalbumin; 1–6, layers of dorsolateral prefrontal cortex. Variants in the GAD67 gene. Recently, allelic variants in the GAD67 gene have been reported to be associated with an increased risk for schizophrenia86. Whether and how these variants would result in cell-type specific changes in GAD67 mRNA expression are unknown. Reduced neurotrophin signalling. Signalling by brainderived neurotrophic factor (BDNF) through its receptor, the tyrosine kinase Trk (tropomyosin-related kinase) B receptor (TrkB), promotes the development of GABA neurons and induces the expression of GABA-related proteins, including GAD67, GAT1 and parvalbumin87,88. These effects might be selective for parvalbumin-expressing cortical GABA neurons, as TrkB is predominantly expressed by GABA neurons that express parvalbumin, but not by those that express calretinin89. So, reduced BDNF–TrkB signalling might contribute to the altered expression of GABA-related genes in the DLPFC of individuals with schizophrenia. Consistent with this hypothesis, the mRNA and protein levels for both BDNF and TrkB have been found to be reduced in the DLPFC of individuals with schizophrenia31,90 (FIG. 7), and the expression of these mRNAs seems to decrease early in the course NATURE REVIEWS | NEUROSCIENCE of the illness. Comparisons with the results of other studies indicate that, in individuals with schizophrenia, the decreased tissue levels of these mRNAs represent changes in gene expression rather than a loss of DLPFC neurons91. In contrast to BDNF and TrkB, the mRNA expression of TrkC — the receptor tyrosine kinase for neurotrophin 3 — is unchanged31. The changes in the expression levels of TrkB and GAD67 mRNA were strongly correlated (r = 0.74, P < 0.001) in the same individuals, and this correlation was significantly stronger than that between BDNF and GAD67 mRNAs, indicating that changes in TrkB expression might be a pathogenetic mechanism that results in a reduction in GABA-related gene expression in individuals with schizophrenia. However, these correlations in human studies do not show a causal relationship. Consequently, as a proof of concept test that reduced signalling through TrkB receptors could cause changes in expression of GABA-related genes in schizophrenia, we used TrkB hypomorphic mice in which the insertion of floxed TrkB cDNA (fBZ) resulted in decreased TrkB expression92. Compared with wild-type mice, expression levels of TrkB mRNA in the prefrontal cortex were significantly VOLUME 6 | APRIL 2005 | 3 1 9 REVIEWS nCi/g 140 Schizophrenia Control BDNF mRNA % control 394 201 143 107 82 61 25 100 80 60 40 20 0 BDNF mRNA 0 nCi/g F 1,23 = 18.8 P < 0.001 120 C 140 F 1,24 = 22.4 P < 0.001 TrkB mRNA % control 741 509 397 336 210 129 68 nCi/g 100 80 60 40 20 C 140 GAD67 mRNA % control 3,470 1540 1120 810 550 320 110 GAD67 mRNA 0 120 0 TrkB mRNA 0 100 80 60 40 20 C 140 PV mRNA %control 860 620 390 210 90 0 0 PV mRNA 1 mm 1 mm S F 1,12 = 10.8 P = 0.006 2,080 1,200 S F 1,24 = 19.4 P < 0.001 120 0 nCi/g S 120 100 80 60 40 20 0 C S Figure 7 | Reduced neurotrophin and GABA-related gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia. The autoradiograms show the laminar distribution of brain-derived neurotrophic factor (BDNF), tyrosine kinase Trk (tropomyosin-related kinase) receptor B (TrkB), 67 kD isoform of glutamic acid decarboxylase, (GAD67) and parvalbumin (PV) mRNAs in the dorsolateral prefrontal cortex of a control individual and the reduced levels of these transcripts in a matched individual with schizophrenia. The densities of hybridization signals are presented in pseudocolours according to the calibration scales for each mRNA. Solid and broken lines indicate the pial surface and the border between the grey and white matter, respectively. The bar graphs show the mean (SD) expression of each transcript in individuals with schizophrenia (S) and matched control subjects (C). F, Fisher’s F distribution resulting from the analyses of variance; the subscript numbers indicate the corresponding degrees of freedom. nCi/g, nanoCuries/gram. Modifed, with permission, from REF. 31 (2005) Society for Neuroscience. decreased by 42% and 75% in fBZ/+ and fBZ/fBZ mice, respectively; and in fBZ/fBZ mice, the expression levels of GAD67 and parvalbumin mRNAs in the prefrontal cortex were significantly decreased by 25% and 40%, respectively31 (FIG. 8). In addition, in the fBZ/+ mice, the expression levels of GAD67 and parvalbumin mRNAs were intermediate between the wild-type and fBZ/fBZ mice. The cellular pattern of reduced GAD67 mRNA expression in these mice also precisely paralleled that seen in individuals with schizophrenia27. That is, the density of neurons with detectable levels of GAD67 mRNA was significantly reduced, but the expression level of GAD67 mRNA per neuron was unchanged31. Furthermore, consistent with the selective vulnerability of a GABA neuron 320 | APRIL 2005 | VOLUME 6 subpopulation in schizophrenia, the TrkB genotype did not affect the expression of calretinin mRNA. So, the changes in the expression of GABA-related genes in TrkB hypomorphic mice replicate those found in individuals with schizophrenia at both the tissue and cellular levels. By contrast, although the expression of BDNF mRNA was decreased by 80% in the prefrontal cortex of mice with a neuron-specific inducible knockout of Bdnf 93, there were no changes in the expression levels of GAD67 or parvalbumin mRNAs in these animals, whether the Bdnf knockout was induced during embryogenesis or in adulthood31. These findings indicate that changes in TrkB but not BDNF expression regulate the expression of GABA-related genes in the prefrontal cortex. www.nature.com/reviews/neuro REVIEWS nCi/g 6,840 Wild Type fBZ/+ 140 fBZ/fBZ 120 TrkB mRNA % wild type 2,840 1,400 850 550 TrkB mRNA 60 40 140 4,890 120 GAD67 mRNA % wild type 2,560 1,540 970 590 270 GAD67 mRNA F 2,6 = 11.1, P = 0.010 a b b 100 80 60 40 20 0 nCi/g 140 3,070 120 PV mRNA % wild type 1,580 980 650 410 190 0 80 0 nCi/g 0 100 20 260 0 F 2,6 = 51.1, P < 0.001 a c b 1 mm PV mRNA F 2,6 = 9.92, P = 0.013 a ab b WT fBZ/+ fBZ/fBZ 100 80 60 40 20 0 Figure 8 | Changes in gene expression in the prefrontal cortex of the TrkB hypomorphic mice are similar to those in individuals with schizophrenia. Representative pseudocoloured autoradiograms show the decreased expression of tyrosine kinase Trk (tropomyosin-related kinase) receptor B (TrkB), 67 kD isoform of glutamic acid decarboxylase (GAD67) and parvalbumin (PV) mRNAs in mice that are heterozygous or homozygous for the floxed TrkB (fBZ) locus. In each graph, bars that do not share the same letter (a, b or c) are significantly different (p<0.05). The mean (SD) expression level of each transcript is reduced in a gene-dose dependent fashion. F, Fisher’s F distribution resulting from the analyses of variance; the subscript numbers indicate the corresponding degrees of freedom. nCi/g, nanoCuries/gram; WT, wild type. Modifed, with permission, from REF. 31 © (2005) Society for Neuroscience. Investigating the pathophysiological process The findings reviewed above provide evidence for both a pathological entity (deficient chandelier cell-mediated inhibition in pyramidal neurons) and a pathogenetic mechanism (reduced neurotrophin signalling through the TrkB receptor) in the DLPFC, the dysfunctional activation of which is associated with a core component (working memory deficits) of the clinical syndrome of schizophrenia. However, the explanatory strength of these findings, and their relevance to the development of new treatment interventions, requires the demonstration of a pathophysiological process by which this pathological entity could give rise to this component of the clinical syndrome. In this regard, it is of interest that gamma band oscillations, which reflect the synchronized firing of neuronal networks at 30–80 Hz, are induced and sustained in the DLPFC during the delay period of working memory tasks94. In addition, the amplitude, or power, of gamma band oscillations in the DLPFC seems to increase in proportion to working memory load95. In the frontal cortex of individuals with schizophrenia, phase-locking of gamma activity in response to the stimulus onset is impaired96, and the power of gamma band oscillations in the DLPFC is reduced during the delay period of a working memory task97. Interestingly, different subpopulations of GABA neurons seem to be specialized to selectively regulate the output of pyramidal cells, giving rise to oscillatory activity in different frequency bands98–100. For example, networks of parvalbumin-expressing, fast spiking GABA neurons NATURE REVIEWS | NEUROSCIENCE in the middle cortical layers, formed by both chemical and electrical synapses, give rise to oscillatory activity in the gamma band range, whereas multipolar bursting GABA neurons in the superficial layers that express both parvalbumin and calbindin give rise to theta frequency (4–7 Hz) oscillations100. The coordinated oscillatory context that is provided by these networks of inhibitory neurons is thought to create the discrete temporal structure that is necessary for ensembles of pyramidal neurons to perform specific functions, such as those involved in working memory. So, a deficit in the synchronization of pyramidal cells, which results from impaired perisomatic inhibition by parvalbumin-expressing GABA neurons, might contribute to the reported deficits in gamma band oscillations, and, consequently, to working memory dysfunction, in individuals with schizophrenia. Several features of parvalbumin-expressing neurons, and of their changes in schizophrenia, could explain how this might occur. First, the axonal arborizations of individual chandelier neurons are highly divergent and target the axon initial segments of a large number of pyramidal neurons.A single chandelier cell can provide inputs to >200 pyramidal neurons within a 100–150 µm radius101 and can thereby regulate the firing of local groups of pyramidal neurons98. Second, in the monkey DLPFC, parvalbumin-expressing GABA neurons and pyramidal cells share certain excitatory inputs, including projections from neighbouring pyramidal neurons and from the mediodorsal thalamus102–104. Excitatory input from these sources stimulates both parvalbumin-expressing and pyramidal neurons VOLUME 6 | APRIL 2005 | 3 2 1 REVIEWS simultaneously, which results in a secondary, temporally delayed perisomatic inhibitory input to pyramidal neurons. This disynaptic inhibitory input seems to limit the window of time, and thereby increases the temporal precision, for the summation of the excitatory inputs that are needed to evoke pyramidal neuron firing105. Consequently, a deficiency in inhibitory perisomatic input to pyramidal neurons would be expected to reduce the magnitude of pyramidal cell synchrony, and, therefore, the power of gamma band oscillation, in the DLPFC. This interpretation predicts that some changes in parvalbumin-expressing GABA neurons in schizophrenia represent compensatory, but inadequate, responses to the deficit in GABA synthesis in these neurons. For example, by buffering presynaptic Ca2+ transients, parvalbumin is thought to reduce the Ca2+-dependent facilitation of GABA release106. During periods of repetitive firing, parvalbumin binds Ca2+ molecules, thereby reducing the level of residual intraterminal Ca2+, which results in decreased GABA release. Consistent with this interpretation, in parvalbumin-knockout mice, GABA release from fast-spiking neurons is facilitated and is associated with an increase in the power of gamma band oscillations106. Similarly, although the level of GAT1 does not seem to affect single inhibitory postsynaptic currents (IPSCs), the blockade of GABA reuptake prolongs the duration of IPSCs when synapses that are close to each other are synchronously activated107. The prolongation of IPSCs, in turn, leads to an increased probability of IPSC summation and, therefore, enhanced efficacy of IPSC trains. This observation is of particular relevance to the inputs of chandelier neurons to pyramidal cell axon initial segments, where the GABA synapses are close together and the presynaptic action potential reaches them almost simultaneously. So, a combined reduction in parvalbumin and GAT1 proteins in the chandelier axon cartridges of individuals with schizophrenia could function synergistically to increase the efficacy of GABA neurotransmission at pyramidal cell axon initial segments during the types of repetitive activity that are associated with working memory. However, these compensatory mechanisms and the upregulation of postsynaptic GABAA receptors are not adequate to overcome the effects of decreased GABA synthesis in schizophrenia. Treatment implications BENZODIAZEPINE Benzodiazepines bind to GABAA receptors, where they increase the frequency of opening of Cl– channels in the presence of GABA, but do not directly open channels in the absence of GABA. At present, the available benzodiazepines are not selective for GABAA receptors that contain the α2 subunit, and so produce a range of effects, such as the sedation mediated by the α1 subunit, which can impair cognitive processes. 322 | APRIL 2005 | VOLUME 6 The real value of understanding the pathophysiology of schizophrenia rests in the prediction of novel targets for pharmacological intervention. The observations reviewed above indicate that drugs with selective agonist activity at α2 subunit-containing GABAA receptors could provide an effective approach for enhancing chandelier neuron inhibition of DLPFC pyramidal neurons in schizophrenia, by increasing the synchronization of pyramidal cell firing at gamma frequencies, and consequently improving working memory function108. The α2 subunit of the GABAA receptor represents a selective target for enhancing inhibition at the axon initial segment of pyramidal neurons because it is predominantly restricted to this location54. In addition, the increased density of α2 containing GABAA receptors at pyramidal neuron axon initial segments in individuals with schizophrenia58 indicates that it might be possible to devise dosing strategies that would activate these receptors without affecting synaptic sites in other brain regions that have normal levels of the GABAA receptor α2 subunit. Such differential activation could reduce potential side effects. Drugs that directly activate α2-containing GABAA receptors independently of the presence of GABA, or those that generally increase the firing rate of chandelier cells, might disrupt the timing of disynaptic inhibition of pyramidal neurons. Furthermore, agents that inhibit GABA reuptake non-selectively could function too broadly, and, in individuals with schizophrenia, the decrease in the level of GAT1 expression in chandelier neurons indicates that the brain has already used this compensatory approach. By contrast, drugs that augment the release of GABA by chandelier cells during normal firing, or those that enhance the postsynaptic response to the release of GABA from chandelier cell axons, such as a GABAA α2-selective BENZODIAZEPINE, might be expected to improve disynaptic inhibition. So, treatment with an α2-selective benzodiazepine would be predicted to augment the postsynaptic inhibitory response at pyramidal neuron axon initial segments in a manner that incorporates the crucial timing of chandelier neuron firing, which is essential for synchronizing pyramidal neuron activity. Furthermore, as the anxiolytic effects of benzodiazepines seem to be mediated by α2 subunit-containing GABAA receptors109, α2-specific agents might both improve cognitive function and reduce the stress responses that have been linked to the exacerbation of psychotic symptoms in individuals with schizophrenia110. Understanding schizophrenia As summarized in FIG. 1, the findings reviewed in this article converge on the idea that a deficiency in TrkB signalling is a pathogenetic mechanism that produces reduced GAD67 mRNA expression and GABA synthesis in the parvalbumin-expressing subpopulation of GABA neurons in the DLPFC of individuals with schizophrenia. Despite the apparent compensatory responses, which include a decrease in the levels of presynaptic GAT1 and parvalbumin, and upregulation of postsynaptic GABAA receptors, the resulting pathophysiological process — changes in the perisomatic inhibitory regulation of pyramidal neurons that are required for gamma frequency oscillations — contributes to the impairments in working memory function that represent a core feature of the clinical syndrome of schizophrenia. However, these abnormalities in GABA neurons are unlikely to be the only contributors to working memory dysfunction in this disorder. For example, changes in dopamine and glutamate neurotransmission in the DLPFC also seem to be involved111,112. Interestingly, in the monkey DLPFC, dopamine terminals provide synaptic inputs to parvalbumin-expressing, but not calretinin-expressing, GABA neurons113, and parvalbumin-positive cortical neurons express a combination of glutamatergic receptor subunits that differs from those in other populations of GABA neurons114. www.nature.com/reviews/neuro REVIEWS The abnormalities in GABA neurons that contribute to the working memory disturbances and the resulting clinical features of schizophrenia might also have a role in the dysfunction of other cortical regions that have been associated with reduced gamma band synchrony115. The extent to which they can account for other clinical features (for example, psychosis) of the illness remains to 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. Lewis, D. A. & Lieberman, J. A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325–334 (2000). Gottesman I. I. Schizophrenia Genesis: The Origins of Madness (Freeman, New York, 1991). Owen, M. J., Williams, N. M. & O’Donovan, M. C. The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry 9, 14–27 (2004). Lewis, D. A. & Levitt, P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25, 409–432 (2002). American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edn (American Psychiatry Association, Washington, D.C., 1994). Elvevåg, B. & Goldberg, T. E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 1–21 (2000). Davidson, M. et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am. J. Psychiatry 156, 1328–1335 (1999). Saykin, A. J. et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 51, 124–131 (1994). Sitskoorn, M. M., Aleman, A., Ebisch, S. J., Appels, M. C. & Kahn, R. S. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr. Res. 71, 285–295 (2004). Green, M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321–330 (1996). This review showed the central importance of cognitive deficits in long-term functional outcome in inidividuals with schizophrenia. Blum, B. P. & Mann, J. J. The GABAergic system in schizophrenia. Int. J. Neuropsychopharmacol. 5, 159–179 (2002). Benes, F. M. & Berretta, S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25, 1–27 (2001). Miller, E. K. & Cohen, J. D. An integrative theory of prefrontal cortex function. Annu. Rev. Neurosci. 24, 167–202 (2001). Weinberger, D. R., Berman, K. F. & Zec, R. F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 43, 114–124 (1986). This seminal investigation showed that dysfunction of the prefrontal cortex, as reflected in reduced cerebral blood flow, was prominent when individuals with schizophrenia were asked to perform certain cognitive tasks. Perlstein, W. M., Carter, C. S., Noll, D. C. & Cohen, J. D. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am. J. Psychiatry 158, 1105–1113 (2001). Callicott, J. H. et al. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 160, 2209–2215 (2003). MacDonald, A. W. et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in a never medicated first-episode psychotic sample. Am. J. Psychiatry (in the press). Barch, D. M., Sheline, Y. I., Csernansky, J. G. & Snyder, A. Z. Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression. Biol. Psychiatry 53, 376–384 (2003). Silver, H., Feldman, P., Bilker, W. & Gur, R. C. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am. J. Psychiatry 160, 1809–1816 (2003). Goldman-Rakic, P. S. Topography of cognition: parallel distributed networks in primate association cortex. Annu. Rev. Neurosci. 11, 137–156 (1988). Goldman-Rakic, P. S. Cellular basis of working memory. Neuron 14, 477–485 (1995). This review clearly summarizes the role of the coordinated, sustained firing of prefrontal pyramidal neurons in working memory. NATURE REVIEWS | NEUROSCIENCE be determined. In addition, the apparent complex interaction between polygenic inheritance and environmental risk factors that determine susceptibility to schizophrenia might prohibit, at least for some time, an understanding of how the etiology of schizophrenia unleashes the pathogenetic mechanisms that give rise to pathological disturbances in cortical GABA neurotransmission. 22. Wilson, F. A., Ó Scalaidhe, S. P. & Goldman-Rakic, P. S. Functional synergism between putative γ-aminobutyratecontaining neurons and pyramidal neurons in prefrontal cortex. Proc. Natl Acad. Sci. USA 91, 4009–4013 (1994). 23. Rao, S. G., Williams, G. V. & Goldman-Rakic, P. S. Destruction and creation of spatial tuning by disinhibition: GABAA blockade of prefrontal cortical neurons engaged by working memory. J. Neurosci. 20, 485–494 (2000). 24. Sawaguchi, T., Matsumura, M. & Kubota, K. Delayed response deficits produced by local injection of bicuculline into the dorsolateral prefrontal cortex in Japanese macaque monkeys. Exp. Brain Res. 75, 457–469 (1989). 25. Constantinidis, C., Williams, G. V. & Goldman-Rakic, P. S. A role for inhibition in shaping the temporal flow of information in prefrontal cortex. Nature Neurosci. 5, 175–180 (2002). 26. Akbarian, S. et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52, 258–266 (1995). The initial report of the now widely replicated deficit in GAD67 mRNA expression in the prefrontal cortex of individuals with schizophrenia. 27. Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R. & Lewis, D. A. Decreased glutamic acid decarboxylase67 mRNA expression in a subset of prefrontal cortical γ-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 57, 237–245 (2000). 28. Guidotti, A. et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 57, 1061–1069 (2000). 29. Mirnics, K., Middleton, F. A., Marquez, A., Lewis, D. A. & Levitt, P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53–67 (2000). This first application of microarray technology to the study of schizophrenia revealed altered expression of a group of genes that encode proteins involved in GABA neurotransmission in the prefrontal cortex of individuals with schizophrenia. 30. Vawter, M. P. et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr. Res. 58, 11–20 (2002). 31. Hashimoto, T. et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 25, 372–383 (2005). 32. Knable, M. B., Barci, B. M., Bartko, J. J., Webster, M. J. & Torrey, E. F. Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers. Mol. Psychiatry 7, 392–404 (2002). 33. Benes, F. M., Todtenkopf, M. S., Logiotatos, P. & Williams, M. Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain. J. Chem. Neuroanat. 20, 259–269 (2000). 34. Asada, H. et al. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem. Biophys. Res. Comm. 229, 891–895 (1996). 35. Asada, H. et al. Cleft palate and decreased brain γ-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 94, 6496–6499 (1997). 36. Markram, H. et al. Interneurons of the neocortical inhibitory system. Nature Rev. Neurosci. 5, 793–807 (2004). A comprehensive review of the various electrophysiological, morphological and molecular characteristics of GABA neurons in rodent cerebral cortex. 37. McBain, C. J. & Fisahn, A. Interneurons unbound. Nature Rev. Neurosci. 2, 11–23 (2001). An excellent review of the functional roles of GABA neurons in cortical function. 38. Lewis, D. A. & Lund, J. S. Heterogeneity of chandelier neurons in monkey neocortex: corticotropin-releasing factor and parvalbumin immunoreactive populations. J. Comp. Neurol. 293, 599–615 (1990). 39. Kawaguchi, Y. Physiological subgroups of nonpyramidal cells with specific morphological characteristics in layer II/III of rat frontal cortex. J. Neurosci. 15, 2638–2655 (1995). The first report that correlated electrophysiological and morphological features of cortical GABA neurons. 40. Somogyi, P. A specific axo–axonal interneuron in the visual cortex of the rat. Brain Res. 136, 345–350 (1977). 41. Condé, F., Lund, J. S., Jacobowitz, D. M., Baimbridge, K. G. & Lewis, D. A. Local circuit neurons immunoreactive for calretinin, calbindin D-28k, or parvalbumin in monkey prefrontal cortex: distribution and morphology. J. Comp. Neurol. 341, 95–116 (1994). 42. González-Burgos, G., Krimer, L. S., Povysheva, N. V., Barrionuevo, G. & Lewis, D. A. Functional properties of fast spiking interneurons and their synaptic connections with pyramidal cells in primate dorsolateral prefrontal cortex. J. Neurophysiol. 93, 942–953 (2005). 43. Kawaguchi, Y. & Kubota, Y. Neurochemical features and synaptic connections of large physiologically-identified GABAergic cells in the rat frontal cortex. Neuroscience 85, 677–701 (1998). 44. Zaitsev A. V. et al. Localization of calcium-binding proteins in physiologically and morphologically characterized interneurons of monkey dorsolateral prefrontal cortex. Cereb. Cortex 8 December 2004 (doi:10.1093/cercor/bhh218). 45. Melchitzky, D. S., Eggan, S. M. & Lewis, D. A. Synaptic targets of calretinin-containing axon terminals in macaque monkey prefrontal cortex. Neuroscience 130, 185–195 (2005). 46. Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R. & Lewis, D. A. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry 158, 256–265 (2001). 47. Hashimoto, T. et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23, 6315–6326 (2003). Through the use of subpopulation-specific molecular markers, this study confirmed that the parvalbuminexpressing subpopulation of GABA neurons is particularly vulnerable in schizophrenia. 48. Woo, T.-U., Miller, J. L. & Lewis, D. A. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am. J. Psychiatry 154, 1013–1015 (1997). 49. Beasley, C. L., Zhang, Z. J., Patten, I. & Reynolds, G. P. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol. Psychiatry 52, 708–715 (2002). 50. Woo, T.-U., Whitehead, R. E., Melchitzky, D. S. & Lewis, D. A. A subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl Acad. Sci. USA 95, 5341–5346 (1998). 51. Pierri, J. N., Chaudry, A. S., Woo, T.-U. & Lewis, D. A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am. J. Psychiatry 156, 1709–1719 (1999). 52. Mody, I. & Pearce, R. A. Diversity of inhibitory neurotransmission through GABAA receptors. Trends Neurosci. 27, 569–575 (2004). An excellent review of the specific functional roles of different types of cortical GABAA receptors. 53. Fritschy, J.-M. & Mohler, H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359, 154–194 (1995). 54. Nusser, Z., Sieghart, W., Benke, D., Fritschy, J.-M. & Somogyi, P. Differential synaptic localization of two major γ-aminobutyric acid type A receptor α subunits on hippocampal pyramidal cells. Proc. Natl Acad. Sci. USA 93, 11939–11944 (1996). 55. Loup, F. et al. A highly sensitive immunofluorescence procedure for analyzing the subcellular distribution of GABAA receptor subunits in the human brain. J. Histochem. Cytochem. 46, 1129–1139 (1998). 56. Levitan, E. S. et al. Structural and functional basis for GABAA receptor heterogeneity. Nature 335, 76–79 (1988). VOLUME 6 | APRIL 2005 | 3 2 3 REVIEWS 57. Lavoie, A. M., Tingey, J. J., Harrison, N. L., Pritchett, D. B. & Twyman, R. E. Activation and deactivation rates of recombinant GABAA receptor channels are dependent on α-subunit isoform. Biophys. J. 73, 2518–2526 (1997). 58. Volk, D. W. et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 12, 1063–1070 (2002). The authors showed that the presynaptic reduction in GABA transporters in chandelier axon terminals was associated with an upregulation of postsynaptic α2-containing GABAA receptors in the axon initial segments of pyramidal neurons in individuals with schizophrenia. 59. Pierri, J. N., Volk, C. L., Auh, S., Sampson, A. & Lewis, D. A. Somal size of prefrontal cortical pyramidal neurons in schizophrenia: differential effects across neuronal subpopulations. Biol. Psychiatry 54, 111–120 (2003). 60. Cruz, D. A., Eggan, S. M., Azmitia, E. C. & Lewis, D. A. Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am. J. Psychiatry 161, 739–742 (2004). 61. Jensen, K., Chiu, C. S., Sokolova, I., Lester, H. A. & Mody, I. GABA transporter-1 (GAT1)-deficient mice: differential tonic activation of GABAA versus GABAB receptors in the hippocampus. J. Neurophysiol. 90, 2690–2701 (2003). 62. Erickson, S. L. & Lewis, D. A. Postnatal development of parvalbumin- and GABA transporter-immunoreactive axon terminals in monkey prefrontal cortex. J. Comp. Neurol. 448, 186–202 (2002). 63. Lewis, D. A., Cruz, D. A., Melchitzky, D. S. & Pierri, J. N. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry 158, 1411–1422 (2001). 64. Hanada, S., Mita, T., Nishino, N. & Tanaka, C. [3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci. 40, 239–266 (1987). 65. Benes, F. M., Vincent, S. L., Marie, A. & Khan, Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75, 1021–1031 (1996). This study showed an increased level of GABAA receptors in the prefrontal pyramidal neurons of individuals with schizophrenia. 66. Akbarian, S. et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb. Cortex 5, 550–560 (1995). 67. Impagnatiello, F. et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl Acad. Sci. USA 95, 15718–15723 (1998). 68. Ohnuma, T., Augood, S. J., Arai, H., McKenna, P. J. & Emson, P. C. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 93, 441–448 (1999). 69. Benes, F. M., Kwok, E. W., Vincent, S. L. & Todtenkopf, M. S. Reduction of nonpyramidal cells in section CA2 of schizophrenics and manic depressives. Biol. Psychiatry 44, 88–97 (1998). 70. Heckers, S. et al. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch. Gen. Psychiatry 59, 521–529 (2002). 71. Cotter, D. et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol. Psychiatry 51, 377–386 (2002). 72. Woo, T.-U., Walsh, J. P. & Benes, F. M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 61, 649–657 (2004). 73. Konopaske, G. T., Sweet, R. A. & Lewis, D. A. GABA transporter-1 immunoreactivity in auditory association cortex in schizophrenia. Soc. Neurosci. Abstr. 34, 110.11 (2004). 74. Pesold, C. et al. Reelin is preferentially expressed in neurons synthesizing γ-aminobutyric acid in cortex and hippocampus of adult rats. Proc. Natl Acad. Sci. USA 95, 3221–3226 (1998). 75. Liu, W. S. et al. Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proc. Natl Acad. Sci. USA 98, 3477–3482 (2001). 76. Pesold, C., Liu, W. S., Guidotti, A., Costa, E. & Caruncho, H. J. Cortical bitufted, horizontal, and Martinotti cells preferentially express and secrete reelin in perineuronal nets, postsynaptically modulating gene expression. Proc. Natl Acad. Sci. USA 96, 3217–3222 (1999). 324 | APRIL 2005 | VOLUME 6 77. Dorph-Petersen, K.-A., Pierri, J. N., Sun, Z., Sampson, A. R. & Lewis, D. A. Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. J. Comp. Neurol. 472, 449–462 (2004). 78. Volk, D. W. & Lewis, D. A. Effects of a mediodorsal thalamus lesion on prefrontal inhibitory circuitry: implications for schizophrenia. Biol. Psychiatry 53, 385–389 (2003). 79. Glantz, L. A. & Lewis, D. A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 57, 65–73 (2000). 80. Garey, L. J. et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry 65, 446–453 (1998). 81. Coyle, J. T., Tsai, G. & Goff, D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. NY Acad. Sci. 1003, 318–327 (2003). 82. Morris, B. J., Cochran, S. M. & Pratt, J. A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101–106 (2005). 83. Bertolino, A. et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 153, 1554–1563 (1996). 84. Lipska, B. K. & Weinberger, D. R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223–239 (2000). 85. Lipska, B. K., Lerman, D. N., Khaing, Z. Z., Weickert, C. S. & Weinberger, D. R. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur. J. Neurosci. 18, 391–402 (2003). 86. Addington, A. M. et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol. Psychiatry 26 Oct 2004 (doi:10.1038/sj.mp.4001599). 87. Yamada, M. K. et al. Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. J. Neurosci. 22, 7580–7585 (2002). 88. Huang, Z. J. et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 98, 739–755 (1999). 89. Cellerino, A., Maffei, L. & Domenici, L. The distribution of brain-derived neurotrophic factor and its receptor trkB in parvalbumin-containing neurons of the rat visual cortex. Eur. J. Neurosci. 8, 1190–1197 (1996). 90. Weickert, C. S. et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 8, 592–610 (2003). 91. Thune, J. J., Uylings, H. B. M. & Pakkenberg, B. No deficit in total number of neurons in the prefrontal cortex in schizophrenics. J. Psychiatr. Res. 35, 15–21 (2001). 92. Xu, B. et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of longterm potentiation through a presynaptic mechanism involving TrkB. J. Neurosci. 20, 6888–6897 (2000). 93. Monteggia, L. M. et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl Acad. Sci. USA 101, 10827–10832 (2004). 94. Tallon-Baudry, C., Bertrand, O., Peronnet, F. & Pernier, J. Induced gamma-band activity during the delay of a visual short-term memory task in humans. J. Neurosci. 18, 4244–4254 (1998). 95. Howard, M. W. et al. Gamma oscillations correlate with working memory load in humans. Cereb. Cortex 13, 1369–1374 (2003). Showed that gamma band power in the human prefrontal cortex increases directly with working memory load. 96. Spencer, K. M., Nestor, P. G., Salisbury, D. F., Shenton, M. E. & McCarley, R. W. Abnormal neural synchrony in schizophrenia. J. Neurosci. 23, 7407–7411 (2003). 97. Cho, R. Y., Konecky, R. O. & Carter, C. S. Impaired task-set maintenance and frontal cortical gamma-band synchrony in schizophrenia. Cognitive Neuroscience Society Annual Meeting (2004). 98. Cobb, S. R., Buhl, E. H., Halasy, K., Paulsen, O. & Somogyi, P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature 378, 75–78 (1995). A seminal study that shows the crucial role of proximal inhibition in synchronizing pyramidal cell output. 99. Tamas, G., Buhl, E. H., Lorincz, A. & Somogyi, P. Proximally targeted GABAergic synapses and gap junctions synchronize cortical interneurons. Nature Neurosci. 3, 366–371 (2000). 100. Blatow, M. et al. A novel network of multipolar bursting interneurons generates theta frequency oscillations in neocortex. Neuron 38, 805–817 (2003). 101. Peters, A. in Cerebral Cortex Vol. 1 (eds Jones, E. G. & Peters, A.) 361–380 (Plenum, New York, 1984). 102. Melchitzky, D. S., Sesack, S. R. & Lewis, D. A. Parvalbuminimmunoreactive axon terminals in macaque monkey and human prefrontal cortex: laminar, regional and target specificity of type I and type II synapses. J. Comp. Neurol. 408, 11–22 (1999). 103. Melchitzky, D. S., González-Burgos, G., Barrionuevo, G. & Lewis, D. A. Synaptic targets of the intrinsic axon collaterals of supragranular pyramidal neurons in monkey prefrontal cortex. J. Comp. Neurol. 430, 209–221 (2001). 104. Melchitzky, D. S. & Lewis, D. A. Pyramidal neuron local axon terminals in monkey prefrontal cortex: differential targeting of subclasses of GABA neurons. Cereb. Cortex 13, 452–460 (2003). 105. Pouille, F. & Scanziani, M. Enforcement of temporal fidelity in pyramidal cells by somatic feed-forward inhibition. Science 293, 1159–1163 (2001). An important investigation that shows the role of feedforward perisomatic inhibition in controlling the timing of pyramidal cell function. 106. Vreugdenhil, M., Jefferys, J. G., Celio, M. R. & Schwaller, B. Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. J. Neurophysiol. 89, 1414–1422 (2003). 107. Overstreet, L. S. & Westbrook, G. L. Synapse density regulates independence at unitary inhibitory synapses. J. Neurosci. 23, 2618–2626 (2003). 108. Lewis, D. A., Volk, D. W. & Hashimoto, T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 174, 143–150 (2004). 109. Löw, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131–134 (2000). 110. Carpenter, W. T. Jr, Buchanan, R. W., Kirkpatrick, B. & Breier, A. F. Diazepam treatment of early signs of exacerbation in schizophrenia. Am. J. Psychiatry 156, 299–303 (1999). 111. Winterer, G. & Weinberger, D. R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 27, 683–690 (2004). 112. Moghaddam, B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881–884 (2003). 113. Sesack, S. R., Hawrylak, V. A., Melchitzky, D. S. & Lewis, D. A. Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures. Cereb. Cortex 8, 614–622 (1998). 114. Kondo, M., Sumino, R. & Okado, H. Combinations of AMPA receptor subunit expression in individual cortical neurons correlate with expression of specific calcium-binding proteins. J. Neurosci. 17, 1570–1581 (1997). 115. Spencer, K. M. et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl Acad. Sci. USA (2004). 116. Cruz, D. A., Eggan, S. M. & Lewis, D. A. Postnatal development of pre- and post-synaptic GABA markers at chandelier cell inputs to pyramidal neurons in monkey prefrontal cortex. J. Comp. Neurol. 465, 385–400 (2003). 117. Lund, J. S. & Lewis, D. A. Local circuit neurons of developing and mature macaque prefrontal cortex: Golgi and immunocytochemical characteristics. J. Comp. Neurol. 328, 282–312 (1993). 118. Diamond, A. in Principles of Frontal Lobe Function (eds Stuss, D. T. & Knight, R. T.) 466–503 (Oxford Univ. Press, London, 2002). 119. Lewis, D. A., Glantz, L. A., Pierri, J. N. & Sweet, R. A. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann. NY Acad. Sci. 1003, 102–112 (2004). Acknowledgements Work by the authors cited in this manuscript was supported by grants from the National Institutes of Health and by a National Alliance for Research on Schizophrenia and Depression Young Investigator Award (T.H.). The authors thank M. Brady and L. Konopka for excellent assistance with the figures and text. Competing interests statement The authors declare competing financial interests: see Web version for details. Online links DATABASES The following terms in this article are linked online to: Entrez Gene: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene BDNF | GAD65 | GAD67 | GAT1 | TrkB FURTHER INFORMATION Lewis’s Laboratory: www.tnp.pitt.edu Access to this interactive links box is free online. www.nature.com/reviews/neuro